144 ·Filed Jun 24, 2026

QURE

uniQure N.V.
NEUTRAL
Impact 2/10
Horizondays Processed3mo ago SEC0001973379-26-000252
Form 144 — notice of proposed sale of securities
Actionable Insight • Neutral

The sale is pre-planned under a 10b5-1 plan and represents a small portion of the CEO's holdings. No immediate bearish signal; monitor for any acceleration of insider selling or changes to the plan.

DirectionNeutral
Confidencehigh
Horizondays
Latest settled — T+20d ⚠ clustered
QURE ▼ -19.69% at T+20d
NEUTRAL call ✗ call lost -19.69% · α vs SPY -20.22% · entry $49.10 → $39.43
Next anchor: T+60d due 14d ago
Latest observation: T+57 -79.18% FF3 residual α
Entry anchored
Jun 24, 03:59 PM ET
via exchange tick
T+1d
-3.24%
call -3.24% · α -2.52%
$47.51
settled 3mo ago
T+5d
-8.00%
call -8.00% · α -9.56%
$45.17
settled 3mo ago
T+20d
-19.69%
call -19.69% · α -20.22%
$39.43
settled 2mo ago
T+60d
—
call — · α —
—
due 14d ago

Price Chart

Loading chart...

Executive Summary

CEO Matthew C. Kapusta filed a Form 144 notice of intent to sell 6,696 ordinary shares valued at approximately $334,800. The shares stem from vested PSU/RSU positions and a stock option exercise, with sales to occur under a 10b5-1 plan adopted in October 2025. This is a routine, pre-planned sale by the CEO, not a discretionary insider sale, and represents a small fraction of his total holdings.

Key Facts

  • CEO Matthew C. Kapusta filed Form 144 to sell 6,696 ordinary shares.
  • Estimated aggregate value of proposed sale: $334,800.
  • Shares originate from vested PSU/RSU positions and a stock option exercise.
  • Sale is conducted under a 10b5-1 trading plan adopted in October 2025.
  • Kapusta's total holdings (including recent acquisitions) are substantial, with recent positions valued over $9.2M.
  • Filing date: June 24, 2026.

Financial Impact

Proposed sale of 6,696 shares (~$334,800) is small relative to CEO's total holdings and company's $3.1B market cap.

Risk Factors

  • CEO selling even under a plan could be perceived negatively by some market participants.
  • If the company's stock price declines, the sale may be executed at lower prices, but this is a pre-planned trade.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
76% bullish (21 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001973379-26-000252
Document: 0001973379-26-000252-index.html0001973379-26-000252
Document: 0001973379-26-000252.txt0001973379-26-000252
32 reports for QURE
Performance horizon
67% Hit rate 6 of 9 directional calls best @ T+20▲ +27.15%Jul 29, 2026
Filters
Rows
Reports for QURE — sortable, filterable
TypeNow
Sep 2, 2026
4w ago
8-K
BULLISH ★ 7/10
$46.23 $44.47▼ −3.81%▼ −2.85%$23.46 (−49.25%)
Jul 29, 2026
9w ago
8-K
BULLISH ★ 8/10
$40.07 $44.24▲ +10.41%▲ +4.88%$23.46 (−41.45%)
Jul 7, 2026
12w ago
Insider Cluster
BEARISH ★ 5/10
$41.41 $41.52▼ −0.27%▲ +0.29%$23.46 (+43.35%)
Jul 2, 2026
13w ago
Insider Cluster
BEARISH ★ 4/10
$41.81 $44.48▼ −6.39%▼ −5.46%$23.46 (+43.89%)
Jul 2, 2026
13w ago
Insider Cluster
MIXED ★ 5/10
$41.81 $44.48▲ +6.39%▲ +5.46%$23.46 (−43.89%)
Jul 2, 2026
13w ago
144
NEUTRAL ★ 2/10
$41.81 $44.48▲ +6.39%▲ +5.46%$23.46 (−43.89%)
Jun 30, 2026
13w ago
144
NEUTRAL ★ 2/10
$45.17 $41.41▼ −8.32%▼ −8.59%$23.46 (−48.06%)
Jun 25, 2026
14w ago
144
BEARISH ★ 5/10
$47.51 $41.81▲ +12.00%▲ +14.16%$23.46 (+50.62%)
Jun 24, 2026
14w ago
424B5
MIXED ★ 6/10
$49.10 $45.17▼ −8.00%▼ −9.56%$23.46 (−52.22%)
Jun 24, 2026
14w ago
144
NEUTRAL ★ 2/10
$49.10 $45.17▼ −8.00%▼ −9.56%$23.46 (−52.22%)
Showing 10 of 32

US Market Status

Market Closed — Opens Mon (64h 21m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access